Shanghai, September 19, 2022 /PR Newswire/ — everest medicine (HKEX 1952.HK, “Everest” or “the Company”) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address critical unmet medical needs . Asia Pacific announced the appointment of Rogers Yongqing Luo as the CEO of the Company. Mr. Luo will also serve as Executive Director of Everest’s Board of Directors.
With over 25 years of experience in the healthcare industry, Mr. Luo has an extensive leadership track record in clinical development, regulatory affairs and commercialization. Previously, Mr. Luo served as president and general manager of Greater China As CEO of Brii Biosciences and TSB Therapeutics, he spearheaded the rapid registration approval, GMP certification and successful commercialization of the world’s first COVID-19 neutralizing antibody therapy, ambarvimab/romlusevimab combination. ChinaPrior to that, he was the Global Vice President and General Manager of China for Gilead Sciences, where he led eight innovative therapeutics in clinical development, regulatory approval, successful commercialization, and efforts to rapidly expand access to patients. led the ChinaLuo has previously successfully launched several high-profile pharmaceuticals. He has managed sales, marketing, government affairs and market access functions for various large multinational pharmaceutical companies including Roche and Novartis, where he spent two years at Novartis headquarters. Switzerland.
“As Everest Medicines continues to evolve its business strategy and rapidly expand its new product pipeline, Rogers joins us to lead Everest through its next phase of growth to become a fully integrated biopharmaceutical company. excited to do Chinasaid Mr. way fu, Chairman of Everest Medicines and CEO of CBC Group. “Rogers has a strong background as Chief Executive Officer of both a biotechnology start-up and a large multinational pharmaceutical company, with comprehensive scientific insight, proven exceptional leadership and leadership in patient access. Brings a unique set of expertise to Everest, including strong commercial capabilities and a proven successful history of early- and late-stage innovative pipelines Greater ChinaIn particular, Rogers’ leadership will strengthen Everest’s new product development and commercial capabilities as the company advances toward approval of late-stage anchor product candidates such as Nefecon, Xerava, Etrasimod and mRNA vaccines. We look forward to leveraging Rogers’ leadership and industry expertise to create long-term growth and success across our businesses. “
“We are very excited to be joining Everest and look forward to working with this talented, world-class team of scientists and industry experts to further advance our industry leadership. will continue to work with us as we continue to advance our late-stage pipeline towards commercialization, said Rogers Yongqing Luo, CEO of Everest Medicines. continues to invest in its discovery platform to build an innovative therapeutic pipeline for the benefit of patients with unmet needs. Greater China others Asia Pacific To create sustainable, long-term value for the market and for our shareholders. “
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on developing and commercializing innovative medicines that address critical unmet medical needs of patients in the Asian market. Everest Medicines’ management team has deep expertise and a proven track record of high-quality clinical development, regulatory affairs, CMC, business development and operations. China We partner with a leading global pharmaceutical company. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development. Our therapeutic areas of interest include oncology, autoimmune diseases, cardiorenal diseases and infectious diseases. For more information, please visit: www.everestmedicines.com.
Forward-Looking Statements:
This news release may make statements that constitute forward-looking statements. This includes statements regarding the intentions, beliefs or current expectations of the Company or its officers regarding the Company’s business operations and financial condition. “will”, “expect”, “expect”, “future”, “intend”, “plan”, “believe”, “estimate”, “believe” and similar statements. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors. Some of which are beyond our control and unpredictable. Accordingly, actual results may differ from forward-looking statements as a result of various factors and assumptions, including future changes and developments in our business, the competitive environment, political, economic, legal and social conditions. may vary. The Company or its affiliates, directors, officers, advisors or representatives make no forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. does not undertake any obligation or promise to revise any forward-looking statements. .
source everest medicine
